- Home
- CRVS vs RXT Comparison
CRVS vs RXT Comparison
Compare CRVS & RXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- RXT
- Stock Information
- Founded
- CRVS 2014
- RXT 1998
- Country
- CRVS United States
- RXT United States
- Employees
- CRVS N/A
- RXT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- RXT EDP Services
- Sector
- CRVS Health Care
- RXT Technology
- Exchange
- CRVS Nasdaq
- RXT Nasdaq
- Market Cap
- CRVS 516.0M
- RXT 509.8M
- IPO Year
- CRVS 2016
- RXT 2020
- Fundamental
- Price
- CRVS $4.99
- RXT $2.25
- Analyst Decision
- CRVS Buy
- RXT Hold
- Analyst Count
- CRVS 4
- RXT 6
- Target Price
- CRVS $12.83
- RXT $2.47
- AVG Volume (30 Days)
- CRVS 1.6M
- RXT 772.4K
- Earning Date
- CRVS 11-12-2024
- RXT 11-12-2024
- Dividend Yield
- CRVS N/A
- RXT N/A
- EPS Growth
- CRVS N/A
- RXT N/A
- EPS
- CRVS N/A
- RXT N/A
- Revenue
- CRVS N/A
- RXT $2,771,200,000.00
- Revenue This Year
- CRVS N/A
- RXT N/A
- Revenue Next Year
- CRVS N/A
- RXT N/A
- P/E Ratio
- CRVS N/A
- RXT N/A
- Revenue Growth
- CRVS N/A
- RXT N/A
- 52 Week Low
- CRVS $1.30
- RXT $1.45
- 52 Week High
- CRVS $10.00
- RXT $3.41
- Technical
- Relative Strength Index (RSI)
- CRVS 28.00
- RXT 37.73
- Support Level
- CRVS $3.77
- RXT $2.47
- Resistance Level
- CRVS $7.44
- RXT $2.46
- Average True Range (ATR)
- CRVS 0.60
- RXT 0.13
- MACD
- CRVS -0.41
- RXT -0.04
- Stochastic Oscillator
- CRVS 25.85
- RXT 16.98
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.